Orforglipron is Lilly’s oral GLP-1 in phase 3 development as a treatment for diabetes and obesity. The FDA is expected to approve the drug in March 2026. Lilly’s November news release states that the ...
Medicare prices are rising in 2026, but savvy seniors can save during open enrollment (and beyond) with these cost-cutting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback